Evidence map›Paper›PMID 38561624›Full record

ReviewCurrent cancer drug targets2025

Review Deciphering the Potential of Nanotherapeutics in Lung Cancer Management.

Prashant Chauhan, Pratibha Pandey, Seema Ramniwas, Fahad Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Prashant ChauhanDepartment of Biotechnology, Noida Institute of Engineering and Technology, Greater Noida, Uttar Pradesh, India.
Pratibha PandeyDepartment of Biotechnology, Noida Institute of Engineering and Technology, Greater Noida, Uttar Pradesh, India.
Seema RamniwasUniversity Centre of Research and Development, University Institute of Biotechnology, Chandigarh University Gharuan, Mohali, Punjab, India.
Fahad KhanDepartment of Biotechnology, Noida Institute of Engineering and Technology, Greater Noida, Uttar Pradesh, India.
Noida International University · INChandigarh University · INJaypee Institute of Information Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains a formidable challenge in oncology, necessitating the development of more effective prognostic and diagnostic techniques due to inefficient conventional therapeutic approaches and inadequate methods for early lung cancer diagnosis. Despite immense progress in the development of innovative strategies to alleviate the impact of this devastating disease, the outcomes, unfortunately, remain unsatisfactory, particularly in targeted drug delivery methods. Consequently, nanotechnology has emerged as a revolutionary force in cancer research to develop more effective targeted drug delivery tools due to its extraordinary capacity at the atomic and molecular levels. It has appeared as a beacon of hope in this area of unmet need, providing innovative ways for the prognosis and diagnosis of lung carcinoma. Therefore, this comprehensive review delves into the evolving field of nano-based therapeutics, shedding light on their potential to transform lung cancer treatment. This study meticulously explores the most promising nano-based strategies that have been extensively linked with the treatment of lung carcinoma and mainly emphasizes targeted drug delivery methods and therapies. Additionally, this review encapsulates the favorable results of clinical trials, which support the potential pathways for further development of nanotherapeutics in lung cancer management.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsLung NeoplasmsNanomedicineNanoparticlesAnimalsHumansNanotechnologyAntineoplastic Agentsclinical trials.immune checkpoint inhibitorsNanocarriersnanotherapeuticsphotothermal therapytargeted therapy

Identifiers

PMID38561624
OpenAlexW4393444554

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.